tradingkey.logo

BRIEF-Eli Lilly Says Most Patients On Omvoh® For Crohn's Disease Achieved Remission And Endoscopic Response At Two Years

ReutersFeb 7, 2025 12:04 PM

- Eli Lilly and Co LLY.N:

  • MOST PATIENTS ON LILLY'S OMVOH® (MIRIKIZUMAB-MRKZ) FOR CROHN'S DISEASE ACHIEVED SUSTAINED CLINICAL REMISSION AND ENDOSCOPIC RESPONSE AT TWO YEARS

  • ELI LILLY AND CO - NEARLY 90% OF PATIENTS SUSTAIN ENDOSCOPIC RESPONSE AT TWO YEARS

Source text: ID:nPnbZkPwFa

Further company coverage: LLY.N

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI